Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15551712 | 0.77 | HRH3 (0.44) | MAPTPOLBHRH3 | |
| SCHEMBL15387590 | 0.77 | POLB (0.35) | POLBHRH3BRD4 | |
| SCHEMBL2161827 | 0.72 | POLB (0.43) | MAPTPOLB | |
| SCHEMBL5435516 | 0.72 | HRH3 (0.41) | MAPTPOLBHRH3 | |
| SCHEMBL20585124 | 0.69 | ALDH1A1 (0.41) | MAPTPOLB | |
| SCHEMBL12404088 | 0.68 | BRD4 (0.46) | BRD4 | |
| SCHEMBL6096655 | 0.68 | HRH3 (0.32) | HRH3 | |
| SCHEMBL22051147 | 0.67 | HSD17B10 (0.47) | MAPTPOLB | |
| SCHEMBL28613618 | 0.67 | — | — | |
| SCHEMBL28921670 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592590-B2 | Tetrahydrotriazolopyridine compounds as selective MGLU5 receptor potentiators useful for the treatment of schizophrenia | ELI LILLY AND COMPANY (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2519521-B1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | LILLY CO ELI (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2519521-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | Eli Lilly and Company (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20120252838-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | ELI LILLY AND COMPANY (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2011082010-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252838-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | GRM5, GRM1, GRIK5 | MAPT 2271/4885POLB 4275/4885HRH3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.